Source disclosure: March 04, 2026, 15:30 JST
Published by Pulse News Wire: March 04, 2026, 15:44 JST
BrightPath Biotherapeutics Co.,Ltd. [4594.T]
TOKYO, Mar 04 (Pulse News Wire) – Brightpath Biotherapeutics CO.,LTD. (4594.T) completed the exercise of its 20th tranche subscription rights during the period from March 2 to March 4, 2026.
A total of 37,589 subscription rights were exercised, representing 13.7% of the total issuance of 275,000 rights. As of March 4, all subscription rights have been fully exercised, leaving no outstanding rights. In February, there were 37,589 unexercised subscription rights. By the end of March, the number of unexercised subscription rights dropped to zero.
During the month of March, 3,758,900 shares were delivered upon the exercise of subscription rights. On March 4 alone, 3,758,900 shares were transferred, marking the completion of the exercise process. The company adheres to exercise limitations based on listing regulations. As of the latest report, the cumulative number of shares delivered through subscription rights exercises stands at 3,758,900, while the total number of issued shares remains at 111,391,300, resulting in an exercise ratio of 3.4%.
AI-translated content. 🟢 Confidence: High See terms • Original filing